Abstract: The present invention—PROMESYS—relates to methods and tools for diagnosis and prognosis of prostate cancer, patient monitoring/follow-up and prediction of response to treatment of patients with confirmed diagnosis of prostate cancer. The methods conducted in vitro comprise the steps of providing a tissue and/or a body fluid sample, obtained from an individual, and determining DNA methylation status and/or level of one or more genes selected from the group consisting of PRKCB, ADAMTS12, NAALAD2, FILIP1L, ZMIZ1 and KCTD8 in a sample. Additionally, methylation status and/or level of CCDC181, MT1E, APC and/or RASSF1 can be included in the biomarker panel for improved performance. Furthermore, the present invention refers to kits and oligonucleotides for use in such a method.